Global Blood-Brain Barrier Market to 2026 - Market is Expected to Reach USD $5.7 Billion

DUBLIN, Sept 24, 2018 /PRNewswire/ --

The "Global Blood-Brain Barrier Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

The blood brain barrier market was valued at USD 496.4 Mn in 2016, and is expected to reach USD 5,704.2 Mn by 2026, expanding at a CAGR of 25.0% from 2018 to 2026.

Market Insights

The blood-brain barrier (BBB) plays important role in protecting the brain from toxic compounds and blood-borne disorders. Thus, in case of central nervous system diseases it is vital to get treatments across this barrier and deliver desired effect at targeted location. According to experts, more than 98% of small molecules drugs and nearly 100% of larger biologic drugs cannot enter the brain at adequate concentrations to project therapeutic effects. The three main BBB permeation mechanisms that occur are passive diffusion, endocytosis, and active transport.

Passive diffusion occurs by two mechanisms free and facilitated, endocytosis occurs by bulk phase and facilitated, and active transport through influx and efflux. Technological development has introduced several key approaches for brain targeting include transport mechanisms such as cell-mediated endocytosis, reticence of active efflux pumps, adsorptive-mediated transcytosis, receptor-mediated transport, and the use of peptide vectors. Drug delivery technologies comprise delivery with assistance of liposomes, nanoparticles, nanogels, dendrimers, nanoemulsions, micelles, exosomes, polymersomes, and quantum dots.

According to market experts, increasing prevalence of neurological diseases, growing geriatric population, rising healthcare expenditure, mounting investment in pharmaceutical research and development, high awareness associated with chronic neurological diseases, and supportive policies and awareness campaigns organized by government organizations are observed as the key driving factors for significant growth of blood-brain barrier market.

By technology blood-brain barrier market is segmented as bispecific antibody RMT approach, Trojan Horse approach, increasing the permeability of BBB, passive diffusion, and other non-invasive BBB technologies. In year 2016, Trojan Horse approach was observed as largest segment in BBB market due to key factors such as the ability to deliver bispecific antibodies to the brain at therapeutic doses and its high membrane permeability.

However, bispecific antibody RMT approach is expected to be the fastest growing segment due to entry of novel BBB technologies such as Ossianix Blood-Brain Barrier Technology (Ossianix) and Brain Shuttle Technology (Roche). Rising application of these two technologies in brain tumor treatment is expected to boost the overall growth of the segment throughout the forecast period 2018 - 2026.

On the basis of diseases, blood-brain barrier market was segmented as Alzheimer's disease, Epilepsy, Parkinson's disease, multiple sclerosis, Hunter's syndrome, and Brain Cancer. In 2016, the BBB market was dominated by Alzheimer's and Parkinson's disease with more than 50% of the market share collectively owing to peaking prevalence of these diseases, introduction of technologically upgraded diagnostic technology for neurological diseases, and increasing awareness programs organized by non-governmental and governmental organizations.

According to World Health Organization (WHO), around 50 million people globally have epilepsy, which makes it one of the most common neurological diseases globally and approximately 80% of the people with epilepsy live in low- and middle-income countries. Thus, incessant technological developments in the field of BBB is expected to assist the market growth throughout the forecast period 2018 - 2026.

Market Competition Assessment:

The blood brain barrier market is the most competitive market comprising large number of players with wide range of products and ongoing research and developments studies. The key players in this market are F. Hoffmann La-Roche, Ltd., Ossianix, Inc., Eli Lilly And Company, Bristol-Myers Squibb Company, Sanofi Genzyme, biOasia Technologies, Inc., Envivo Pharmaceuticals, Inc., Sagetis Biotech, Janssen Pharmaceutica NV, and ArmaGen among others.

Key Market Movements

• Rising prevalence of neurological diseases coupled with rise in treatment limitations associated with blood-brain barrier
• Incessant growth in research and development activities carried out in BBB technologies market

Key Topics Covered:

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology

Chapter 2. Executive Summary
2.1. Global Blood-Brain Barrier Market Portraiture
2.2. Global Blood-Brain Barrier Market, By Disease Type, 2017 (US$ Mn)
2.3. Global Blood-Brain Barrier Market, By Technology Type, 2017 (US$ Mn)
2.4. Global Blood-Brain Barrier Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Blood-Brain Barrier Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Blood-Brain Barrier Technologies: Future Trends
3.3. Current Scenario: Strategies Used for Drug Delivery Across BBB Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Blood-Brain Barrier Market, by Disease Type, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Alzheimer's Disease
4.3. Epilepsy
4.4. Parkinson's Disease
4.5. Multiple Sclerosis
4.6. Hunter's Syndrome
4.7. Brain Cancer

Chapter 5. Global Blood-Brain Barrier Market, By Technology, 2016 - 2026 (US$)
5.1. Overview
5.2. Bispecific Antibody RMT Approach
5.2.1. Ossianix Blood-Brain Barrier Technology (Ossianix)
5.2.2. Brain Shuttle Technology (Roche)
5.2.3. Other Bispecific Antibodies Based Technologies
5.3. Trojan Horse Approach
5.3.1. Transcend Technology (biOasis)
5.3.2. LRP Technology (Angiochem)
5.3.3. IPRO Technology (Iproteos)
5.3.4. ArmaGen Technology Platform (ArmaGen)
5.3.5. Vect-Horus Technology Platform (Vect-Horus)
5.3.6. G-Technology (BBB Therapeutics)
5.3.7. Nano BBB Technology Platform (Sagetis Biotech)
5.3.8. Other Technologies Based on Trojan Horse Approach
5.4. Increasing the Permeability of BBB
5.4.1. SonoCloud Technology (CarThera)
5.4.2. SPG Technology (BrainsGate)
5.4.3. Other Technologies Based on Increasing Permeability of BBB
5.5. Passive Diffusion
5.5.1. SciFluor Life Sciences
5.6. Other Non-Invasive BBB Technologies
5.6.1. SMART Molecule Technology (ICBI)
5.6.2. Molecular Envelope Technology (Nanomerics)
5.6.3. Other Approaches (JCR Pharma, Cyclenium, Cerecor, Lauren Sciences, Protheragen)

Chapter 6. Global Blood-Brain Barrier Market: Pipeline Analysis
6.1. Overview
6.2. SonoCloud
6.3. MRI-guided laser ablation + Doxorubicin + Etoposide + Dynamic contrast-enhanced (DCE) MRI
6.4. P03277 + Gadobenate dimeglumine + MRI
6.5. Carboplatin + Mannitol + Melphalan + Sodium Thiosulfate
6.6. Intra-arterial Cerebral Infusion of Trastuzumab
6.7. 25% Mannitol + Low-dose Intra-arterial Bevacizumab

Chapter 7. Global Blood-Brain Barrier Market, by Geography, 2016 - 2026 (US$ Mn)

Chapter 8. Company Profiles

• Allon Therapeutics, Inc.
• Angiochem Inc.
• Armagen Technologies, Inc.
• BrainsGate
• Bristol-Myers Squibb
• BiOasis Technologies, Inc.
• Cephalon Inc.
• Cerecor
• CarThera
• Cytos Biotechnology AG
• Envivo Pharmaceuticals, Inc.
• Eli Lilly And Company
• Sanofi Genzyme
• Iproteos S.L.
• Janssen Pharmaceutica NV
• Nanomerics
• Ossianix, Inc.
• Protheragen, Inc.
• F. Hoffman La-Roche
• Shire plc

For more information about this report visit

https://www.researchandmarkets.com/research/xgc75z/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets